Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
Date:3/8/2010

1 million -- GAAP diluted earnings per ADS was 72 cents, versus a loss in the prior-year period -- Non-GAAP diluted earnings per ADS grew 11% year over year to 89 cents

Management Comment

"WuXi had a strong fourth quarter and a successful 2009," said Dr. Ge Li, Chairman and Chief Executive Officer. "We achieved all of our publicly stated financial goals. We were able to achieve solid revenue growth in 2009, led by a strong performance by our China-based Laboratory Services business, which achieved revenues at the top of its guidance range. Full-year 2009 adjusted EBITDA(1) exceeded our expectations.

"We expect another good year in 2010. We are targeting 2010 revenues to grow 15-19% above 2009 levels, driven by 13-16% growth in revenues of our China-based Laboratory Services business and an improving Manufacturing Services business. We believe that these rates of growth remain at or near the top of our industry. At the same time, 2010 will be a transition year, as we continue to invest in our China-based Laboratory Services, large-scale manufacturing, and toxicology businesses. In spite of these investments, operating income in 2010 will grow by up to 10%. We expect these investments will drive accelerating growth in revenues and operating income in 2011 and beyond.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
2. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
3. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
4. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
5. WuXi PharmaTech Announces Second-Quarter 2009 Results
6. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
7. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
8. WuXi PharmaTech Receives Award from BASF
9. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Hospital Energy Performance Service can help ... energy efficiency by 25% or more ... The service is available from Environmental Health ... and engineering consulting firm."Healthcare facilities are heavy energy users and ...
... Inc., a privately-held specialty pharmaceutical company, announced today that ... evaluate EVK-001 for the treatment of adults with symptoms ... delayed emptying of the stomach into the intestine following ... is an important cause of gastroparesis, but other identified ...
... Mass., May 5 Syrinx Consulting Corporation ... that delivers easy-to-use .Net and SharePoint applications ... contract for approximately $100,000 with a leading biopharmaceutical company ... migrating thousands of users and gigabytes of data from ...
Cached Biology Technology:New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2
(Date:4/15/2014)... American Association of Anatomists (AAA) is honored to announce ... presented during the Closing Awards Ceremony being held at ... at 7:30 p.m. during AAA,s 2014 Annual Meeting at ... winners are: , Henry Gray/Elsevier Distinguished Educator ... of Medicine at Mount Sinai, Past-President of the American ...
(Date:4/15/2014)... In recent years, it has become clear that ... previously assumed. In addition to the well-known building ... variations play an important role. Scientists now assume ... form a second layer of information that extends ... are rather like umlauts that extend the standard ...
(Date:4/14/2014)... subarctic forest moths in Finnish Lapland suggests that scientists ... animals and plants because much of the harm is ... 80 moth species and found that 90 percent of ... period, from 1978 to 2009. During that time, average ... Fahrenheit, and winter precipitation increased as well. , "You ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2German Research Foundation approves new priority program in the life sciences 2Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3
... They may never win an Oscar, but scientists at ... have developed techniques for creating accurate movies of biological ... now. Biological and organic molecules in solution ... of salt or metals since they are constantly moving ...
... increased risk of wheezing in the chest if they take part ... shown in a new study using data from the Norwegian Mother ... (NIPH). The results come from a study of ... children took part in baby swimming from 0-6 months of age. ...
... is available in French . , ... Management, the private bankers Lombard Odier Darier Hentsch & ... at EPFL dedicated to sustainable development. The chair is ... fundamental and social sciences in the environmental domain. ...
Cached Biology News:Argonne scientists develop techniques for creating molecular movies 2Possible link between baby swimming and breathing problems in children 2EPFL Research Day 2008, in the presence of Al Gore 2EPFL Research Day 2008, in the presence of Al Gore 3
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Cy3 Ab Labeling Kit, 1 kit. ... CyDye fluorescent dyes. Conjugations are carried ... within 1 h. Dyes are packaged ... ensure consistent labelings. Category: Blotting & ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: